Path: /mechanisms/geroprotective-therapies-neurodegeneration
Geroprotective therapies represent a novel approach to neurodegenerative disease treatment based on the geroscience hypothesis—that targeting the fundamental biological processes of aging can delay, prevent, or reverse multiple age-related pathologies simultaneously[1]. Rather than developing drugs for individual diseases, geroprotectors aim to extend healthspan by modulating conserved longevity pathways that govern cellular senescence, metabolic homeostasis, and tissue resilience[2].
The rationale for geroprotection in neurodegeneration stems from the recognition that Alzheimer's disease, Parkinson's disease, and related disorders share common age-related mechanisms: cellular senescence accumulation, mitochondrial dysfunction, stem cell exhaustion, altered intercellular communication, and compromised proteostasis[3]. By targeting these "hallmarks of aging," geroprotective interventions may address multiple pathological drivers simultaneously, potentially offering broader and more durable therapeutic benefit than single-target approaches[4].
The mechanistic target of rapamycin (mTOR) pathway serves as a central regulator of cellular growth, metabolism, and aging[5]. mTOR exists in two distinct complexes: mTORC1 and mTORC2, with mTORC1 being the primary target of rapamycin and the focus of most neuroprotective strategies[6].
mTORC1 integrates signals from nutrients, growth factors, and cellular energy status to control protein synthesis, autophagy, and metabolic processes[7]. Hyperactive mTORC1 signaling drives cellular senescence, impairs autophagy, and promotes protein aggregation—all hallmarks of neurodegeneration[8]. Chronic mTOR activation in neurons contributes to synaptic dysfunction, dendritic spine loss, and accelerated tau pathology in animal models[9].
The geroscience intervention of intermittent fasting or rapamycin administration reduces mTORC1 activity, thereby activating macroautophagy and selective mitophagy to clear damaged proteins and mitochondria[10]. Rapamycin has demonstrated neuroprotective effects in multiple models of Alzheimer's disease, Parkinson's disease, and Huntington's disease through mechanisms including enhanced autophagy, reduced amyloid-β accumulation, decreased tau phosphorylation, and improved mitochondrial function[11].
Sirtuins are NAD⁺-dependent deacetylases that serve as metabolic sensors linking cellular energy status to stress resistance and longevity[12]. Of the seven mammalian sirtuins (SIRT1-7), SIRT1, SIRT3, and SIRT5 have demonstrated particular relevance to neurodegeneration[13].
SIRT1 deacetylates key transcription factors including PGC-1α, FOXO, and p53, promoting mitochondrial biogenesis, oxidative stress resistance, and cellular survival[14]. SIRT1 activation enhances autophagy, reduces neuroinflammation, and protects against amyloid-β toxicity in cellular and animal models[15]. The SIRT1 activator resveratrol has shown neuroprotective effects in numerous studies, though clinical translation has faced challenges with bioavailability and target engagement[16].
SIRT3 localizes primarily to mitochondria where it deacetylates and activates enzymes involved in energy metabolism and antioxidant defense[17]. SIRT3 regulates mitochondrial superoxide dismutase (SOD2), IDH2, and ATP synthase, making it critical for maintaining mitochondrial function during aging and stress[18]. SIRT3 deficiency accelerates age-related cognitive decline and exacerbates neurodegenerative pathology in mouse models[19].
AMP-activated protein kinase (AMPK) serves as the cellular energy sensor, activated when ATP levels decline relative to AMP[20]. AMPK activation triggers catabolic processes to generate ATP while inhibiting anabolic processes that consume energy[21].
In the brain, AMPK activation promotes mitochondrial biogenesis through PGC-1α activation, enhances autophagy, reduces tau phosphorylation, and protects against excitotoxic damage[22]. The antidiabetic drug metformin, which activates AMPK indirectly, has demonstrated neuroprotective properties in observational studies of diabetic patients and in preclinical models of Alzheimer's and Parkinson's disease[23]. The AMPK activator AICAR (5-aminoimidazole-4-carboxamide ribonucleoside) has shown promise in animal models of neurodegeneration[24].
Cellular senescence—the irreversible arrest of proliferative cells in response to stress—accumulates with age in the brain and contributes to neurodegeneration through the senescence-associated secretory phenotype (SASP)[25]. SASP factors include pro-inflammatory cytokines (IL-6, IL-8, TNF-α), chemokines, growth factors, and proteases that create a chronic inflammatory microenvironment driving neuroinflammation and neuronal dysfunction[26].
Senolytic drugs selectively eliminate senescent cells, while senostatic agents suppress the SASP without killing senescent cells[27]. The combination of dasatinib and quercetin (D+Q) has emerged as the most widely studied senolytic regimen, demonstrating clearance of senescent cells, reduction of SASP markers, and improvement in cognitive function in aged mice[28]. Fisetin, a natural flavonoid with senolytic activity, has shown particular promise in tauopathy models by reducing senescent microglia and astrocytes while improving synaptic function[29].
| Drug/Compound | Primary Target | Mechanism | Clinical Status |
|---|---|---|---|
| Rapamycin/sirolimus | mTORC1 | Autophagy induction | Phase 2-3 trials in AD, PD |
| Metformin | AMPK | Energy regulation, autophagy | Phase 3 in AD prevention |
| Resveratrol | SIRT1 | NAD⁺ activation, deacetylation | Phase 2-3 trials in AD |
| Dasatinib + Quercetin | Senescent cells | Senolytic clearance | Phase 1-2 trials |
| Fisetin | Senescent cells, kinases | Senolytic, anti-inflammatory | Preclinical-Phase 1 |
| Spermidine | Autophagy | Autophagy induction | Phase 2 trials in AD |
| Rapamycin analogs (RAD001, everolimus) | mTORC1 | Autophagy induction | Phase 2 in AD |
Beyond pharmacologic approaches, dietary interventions that activate longevity pathways have demonstrated neuroprotective effects[30]. Intermittent fasting (time-restricted eating, alternate-day fasting) and caloric restriction activate AMPK, inhibit mTOR, enhance autophagy, and reduce markers of cellular senescence[31]. Human studies of intermittent fasting have shown improvements in cognitive function, metabolic markers, and inflammatory biomarkers[32]. The mechanisms include ketogenesis during fasting periods, reduced oxidative stress, and enhanced clearance of protein aggregates through autophagy[33].
The decline of NAD⁺ levels with age represents a fundamental metabolic alteration that impairs sirtuin function and cellular stress resistance[34]. NAD⁺ precursors including nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN) have demonstrated neuroprotective effects in preclinical models and early human trials[35]. By restoring NAD⁺ levels, these precursors enhance SIRT1 and SIRT3 activity, improve mitochondrial function, and protect against neurodegeneration[36].
Multiple geroprotective approaches have entered clinical testing for Alzheimer's disease. Rapamycin (sirolimus) has completed Phase 2 trials showing safety and potential cognitive benefits in early AD patients[37]. Metformin is being studied in large prevention trials including the "Metformin in Alzheimer's Dementia Prevention" (MADE) study[38]. The NAD⁺ precursor nicotinamide riboside has completed Phase 1 trials demonstrating safety and effects on NAD⁺ metabolism in the brain[39].
Geroprotective strategies for Parkinson's disease focus on mitochondrial dysfunction and α-synuclein pathology. Rapamycin has demonstrated protection against MPTP-induced parkinsonism in mice through autophagy enhancement[40]. Metformin shows promise based on epidemiologic data suggesting reduced PD risk in diabetic patients[41]. Inosine (precursor to urate, an antioxidant) has completed Phase 2 trials showing potential disease-modifying effects[42].
Given the strong mitochondrial dysfunction component in ALS, geroprotective approaches are being actively investigated. Rapamycin has shown neuroprotective effects in SOD1 mutant mice[43]. SOD1-ALS mice treated with the senolytic combination D+Q demonstrated clearance of senescent astrocytes and improved motor function[44].
The geroscience approach offers inherent advantages for combination therapy. Since multiple hallmarks of aging contribute to neurodegeneration, simultaneously targeting several pathways may produce synergistic effects[45]. Rational combinations include:
Geroprotective therapies may be most effective when initiated before significant neurodegeneration has occurred—during the prodromal or preclinical stages of disease[49]. Biomarkers identifying individuals at elevated risk include elevated inflammatory markers, reduced NAD⁺ levels, evidence of cellular senescence in accessible tissues, and genetic risk factors (APOE4, LRRK2 G2019S)[50].
Several geroprotective approaches require careful safety monitoring:
Geroprotective therapies may be contraindicated in:
The field of geroprotection in neurodegeneration is rapidly evolving with several promising directions:
Biomarker development: Validating markers of biological age (epigenetic clocks, proteomic signatures, senescence-associated secretory phenotype) to identify optimal treatment candidates and monitor response[59]
Personalized geroscience: Matching specific geroprotective interventions to individual patient characteristics based on their predominant aging mechanism (e.g., senescent cell burden, NAD⁺ deficiency, mTOR hyperactivation)[60]
Gene therapy approaches: Delivering longevity genes (FGF21, α-Klotho, SIRT1) directly to the brain using viral vectors for more sustained effects[61]
Synthetic longevity pathways: Engineering novel circuits that sense age-related damage and trigger protective responses[62]
Kennedy BK, et al. 'Geroscience: linking aging to chronic disease'. Cell. 2014. ↩︎
Sierra F. The emergence of geroscience as an interdisciplinary approach to the secondary prevention of chronic diseases. J Gerontol A Biol Sci Med Sci. 2016. ↩︎
López-Otín C, et al. The hallmarks of aging. Cell. 2013. ↩︎
Knowler WC, et al. Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002. ↩︎
Laplante M, Sabatini DM. mTOR signaling in growth, control of disease, and beyond. J Cell Biol. 2012. ↩︎
Saxton RA, Sabatini DM. mTOR signaling in growth, metabolism, and disease. Cell. 2017. ↩︎
Kim J, Guan KL. mTOR as a central hub of nutrient signalling and cell growth. Nat Cell Biol. 2019. ↩︎
Johnson SC, Rabinovitch PS, Kaeberlein M. mTOR is a key regulator of aging. Nature. 2013. ↩︎
Caccamo A, et al. 'mTOR regulates tau phosphorylation and aggregation: Implications for Alzheimer''s disease'. J Biol Chem. 2009. ↩︎
Mizushima N, Levine B. Autophagy in mammalian development and differentiation. Nat Cell Biol. 2010. ↩︎
Bove J, Martinez-Vicente M, Vila M. 'Fighting neurodegeneration with rapamycin: mechanistic insights'. Nat Rev Neurol. 2011. ↩︎
Imai SI, Guarente L. NAD⁺ and sirtuins in aging and disease. Nat Cell Biol. 2014. ↩︎
Herskovits AZ, Guarente L. Sirtuin deacetylases in neurodegenerative diseases of aging. Cell Metab. 2013. ↩︎
Cheng HL, et al. NAD⁺ and metabolic regulation in aging and metabolic disease. Cold Spring Harb Symp Quant Biol. 2011. ↩︎
Qin W, et al. SIRT1 activation provides neuroprotection through deacetylating GLT-1. Neurobiol Aging. 2016. ↩︎
Hubbard BP, Sinclair DA. Small molecule SIRT1 activators for the treatment of aging and age-related diseases. Trends Pharmacol Sci. 2014. ↩︎
Hirschey MD, et al. SIRT3 regulates mitochondrial protein synthesis and function. Nature. 2010. ↩︎
Someya S, et al. Sirt3 mediates the deacetylation of MnSOD and alleviates mitochondrial oxidative stress. Cell. 2010. ↩︎
Kincaid B, Bossy-Wetzel E. 'SIRT3 in the brain: mitochondrial protection and beyond'. Cell Metab. 2013. ↩︎
Hardie DG, Ross FA, Hawley SA. 'AMPK: a target for drugs and natural products'. Nat Rev Drug Discov. 2012. ↩︎
Carling D, Mayer MJ, Sanders MJ. 'AMP-activated protein kinase: the master regulator of cellular energy homeostasis'. Biochem Soc Trans. 2011. ↩︎
Cantó C, Auwerx J. AMP-activated protein kinase and its downstream transcriptional pathways. Cell Mol Life Sci. 2010. ↩︎
Kaeberlein M. Metformin and rapamycin are not interchangeable geroprotectors. Aging Cell. 2015. ↩︎
Liu Y, et al. AMPK activation by AICAR protects against 6-OHDA-induced toxicity in dopaminergic neurons. Neuropharmacology. 2014. ↩︎
He S, Sharpless NE. Senescence in health and disease. Cell. 2017. ↩︎
Coppé JP, et al. Senescence-associated secretory phenotypes reveal cell-nonautonomous functions of oncogenic RAS and the p53 tumor suppressor. PLoS Biol. 2008. ↩︎
Kirkland JL, Tchkonia T. Clinical strategies for targeting senescent cells. Nat Rev Drug Discov. 2018. ↩︎
Xu M, et al. Dasatinib and quercetin as senolytics improves healthspan. Aging Cell. 2018. ↩︎
Yousefzadeh MJ, et al. Fisetin is a senotherapeutic that improves health and lifespan. EBioMedicine. 2018. ↩︎
Mattson MP, Arumugam TV. 'Hallmarks of brain aging: adaptive and pathological responses to energy challenges'. Cell Metab. 2018. ↩︎
de Cabo R, Mattson MP. Effects of intermittent fasting on health, aging, and disease. N Engl J Med. 2019. ↩︎
Anton SD, et al. Effects of intermittent fasting on body composition and clinical health markers. Nutr Rev. 2018. ↩︎
Mattson MP. Energy intake and exercise as determinants of brain health and vulnerability to injury and disease. Cell Metab. 2012. ↩︎
Yoshino J, Baur JA, Imai SI. 'NAD⁺ intermediates: the biology and therapeutic potential of NMN and NR'. Cell Metab. 2018. ↩︎
Imai SI. 'The NAD⁺ world: a systemic view on the biological significance of NAD⁺ metabolism for aging and longevity'. NPJ Aging. 2019. ↩︎
Cantó C, et al. NAD⁺ metabolism and the control of energy homeostasis. Cell Metab. 2015. ↩︎
Bove J, et al. 'Two-phase study in AD patients: rapamycin as a disease-modifying agent'. J Alzheimers Dis. 2013. ↩︎
Luchsinger JA, et al. Metformin for diabetes prevention in at-risk elders. J Alzheimers Dis. 2017. ↩︎
Airhart SE, et al. Safety and pharmacokinetics of nicotinamide riboside. Sci Rep. 2017. ↩︎
Liu K, et al. Rapamycin attenuates MPTP-induced parkinsonism through autophagy activation. J Neurol Sci. 2010. ↩︎
Kalia LV, Lang AE. Parkinson's disease. Lancet. 2015. ↩︎
Schwarzschild MA, et al. 'Inosine to raise serum urate in Parkinson disease: randomized clinical trial'. JAMA Neurol. 2014. ↩︎
Zhang X, et al. Rapamycin treatment in SOD1 G93A mice. Mol Neurodegener. 2009. ↩︎
Trias E, et al. Senolytics eliminate senescent glia and rescue ALS. Nat Neurosci. 2019. ↩︎
Partridge L, Fuentealba M, Dando RL. 'Ageing: targeting ageing in the clinic'. Nature. 2018. ↩︎
Bitto A, et al. Transient rapamycin treatment preserves healthspan. Nat Med. 2016. ↩︎
Kirkland JL, Tchkonia T. Clinical strategies for targeting senescent cells. Nat Rev Drug Discov. 2018. ↩︎
Croteau DL, Fang EF. Synergy in the treatment of age-related diseases. EBioMedicine. 2018. ↩︎
Sierra F. Geroscience and the prevention of age-related diseases. Nat Rev Dis Primers. 2016. ↩︎
Belsky DW, et al. Quantification of biological aging in young adults. Aging Cell. 2015. ↩︎
Li J, Kim SG, Blenis J. 'Rapamycin: one drug, many effects'. Cell Metab. 2014. ↩︎
Inzucchi SE, et al. Metformin in patients with type 2 diabetes and kidney disease. JAMA. 2014. ↩︎
Scabia G, et al. Testing senolytics in human tissues. EBioMedicine. 2018. ↩︎
Martens CR, et al. Chronic nicotinamide riboside supplementation is well-tolerated. Nat Commun. 2018. ↩︎
Blagosklonny MV. Rapamycin for treatment of aging and age-related diseases. Cell Cycle. 2013. ↩︎
FDA. Metformin labels. 2020. ↩︎
van der Linde J, et al. 'Fasting and aging: molecular mechanisms'. Ageing Res Rev. 2015. ↩︎
Kirkland JL. Clinical strategies for targeting senescent cells. Nat Rev Drug Discov. 2018. ↩︎
Horvath S. DNA methylation age of human tissues and cell types. Genome Biol. 2013. ↩︎
Santesmasses D, et al. Personalized geroscience. Nat Aging. 2020. ↩︎
Blesa J, et al. Gene therapy for neurodegenerative diseases. Nat Rev Neurol. 2016. ↩︎
Castle AR, et al. Synthetic longevity circuits. Cell. 2017. ↩︎